SGLT-2 inhibition and glucagon: Cause for alarm?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recent studies raised the alarm that the inhibition of sodium-coupled glucose transporter type 2 in humans increases endogenous glucose production rates by an unclear mechanism. Surprisingly, a potential explanation may be linked directly to the alpha-cell. Is this a mechanistic spoiler or an added benefit?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 2×
“After 28 days of treatment, although EGP remained elevated, glucagon had normalized, identifying a potential disconnect [2].”
BackgroundDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 2×
“The initial difference in EGP was driven by a sudden drop in EGP in the placebo group rather than an increase in the treatment arm, and could not be fully explained by measured insulin, glucagon or glucose [1].”
BackgroundBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 2×
“dose insufficient to lower plasma glucose [7].”
BackgroundHeimberg, H., De Vos, A., Pipeleers, D., Thorens, B., & Schuit, F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.15.8971 · Cited by 188
Cited by
Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2316 · Cited by 379
Ogawa, W., & Sakaguchi, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12401 · Cited by 307
“In addition, evidence suggests that the administration of SGLT2 inhibitors stimulates the secretion of glucagon(4), which might be either a secondary effect mediated by the decrease in insulin secretion or a direct effect of SGLT2 inhibitors on pancreatic a-cells.(4) Given that glucagon inhibits acetyl-CoA carboxylase…”
BackgroundManagement of Hyperglycemic Crises
Fayfman, M., Pasquel, F. J., & Umpierrez, G. E. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.12.011 · Cited by 278
Hemodynamic Effects of Glucagon: A Literature Review
Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68
Metadata
- Authors
- Kibbey, R. G.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 26
- Issue
- 7
- Pages
- 337-338
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W1486035726
- Cited by
- 47
- References
- 4
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT-2 inhibition and glucagon: Cause for alarm? https://app.cochat.ai/papers/10.1016/j.tem.2015.05.011
- The paper
- Kibbey, R. G. (2015). SGLT-2 inhibition and glucagon: Cause for alarm? Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2015.05.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.